Background: Over one million men are diagnosed with prostate cancer each year worldwide, with a wide range of research programs requiring access to patient tissue samples for development of improved diagnoses and treatments. Random sampling of prostate tissue is sufficient for certain research studies, however there is a growing research need to target areas of aggressive tumor as fresh tissue. Here we set out to develop a new pathway "PEOPLE: PatiEnt prOstate samPLes for rEsearch" to collect high quality fresh tissue for research use, using magnetic resonance imaging (MRI) to target areas of tumor and benign tissue.
PG14-018-TR2; National Institute for Health Research University College London Hospitals; Biomedical Research Centre Conclusion: Here we report initial data from the PEOPLE pathway; using a method for targeting areas of tumor within prostate samples using MRI. This method operates alongside the standard clinical pathway and minimizes additional input from surgical, radiological and pathological teams, while preserving surgical margins and diagnostic tissue. half immediately in theater, taking research biopsies for freezing and then suturing the prostate back together for fixation. 2 Another method involved slicing the whole prostate fresh in 4 mm slices, and storing one whole slice for research in RNAlater, while the rest were fixed and stored as formalin fixed paraffin embedded (FFPE) blocks for pathological assessment. 3 Sooriakumaran et al 4 published a method in 2011 which involved slicing and taking mapped punch biopsies for immediate storage in RNAlater in theatre, followed by fixation of remaining sections in histology cassettes. The team later confirmed consistently high RNA integrity independent of ischemia time. 5 In order to generate larger frozen specimens suitable for inclusion in the ICGC, another group quartered and flash froze alternate slices of the prostate for biobanking. This resulted in the generation of large amounts research specimens, but also large proportions of surgical margins not being available for routine histological processing, although the banked samples could be accessed later by pathology if required for further diagnostic tests. 6 Our previous prostate sampling publication 7 and studies reporting the efficacy of MRI in diagnosing clinically significant prostate cancer, there is an increasing trend towards using MRI prior to transperineal template biopsy to diagnose patients with suspected prostate cancer. [8] [9] [10] [11] This represents an ideal opportunity to better target research samples, by incorporating a review of MRI data into the sampling procedure.
Here we set out to use MRI to build upon previously published prostate sampling methods, enabling researchers to target specific areas of tumor and benign tissue within radical prostatectomy specimens, and use tissue either immediately fresh, or frozen or fixed as applicable to the specific study requirements. 
| MATERIALS AND METHODS

| Tissue samples
| Tissue sampling from radical prostatectomy specimens
Prostates were collected from theatres immediately upon removal from the patient during robotic radical prostatectomy at UCLH and transported under UN3373 guidelines to the UCLH Pathology Department. If suitable staff were not available to sample the prostate immediately, the specimen was stored at 4°C for up to 24 h in accordance with Genomics England guidelines. The prostate was weighed and inked, and a 5 mm transverse slice was removed using the parallel blade device as previously published. 7 tumor and benign areas were identified and 1-2 samples of each removed as per the requirements of each study, using 3 mm or 6 mm biopsy punches.
tumor regions typically felt slightly denser and occasionally looked paler and this was taken into account when selecting regions to sample.
Remaining tissue was pinned to cork, fixed in 10% neutral buffered formalin and processed as per local protocols. This process was initially carried out by pathologists, and later two trained postdoctoral researchers signed off as competent to carry out the procedure, under supervision of a pathologist.
| Tumor targeting using MRI
All patients received a multiparametric (mp) prostate MRI prior to their robotic radical prostatectomy, either at UCLH or at their referring hospital ( Table 2) . Two methods were used to target tumor samples using MRI data (Table 3 ).
| Initial method
All patients undergoing robotic radical prostatectomy at UCLH are discussed at a surgical planning meeting, where a surgical planning sheet was filled out with details of tumor location according to both biopsy and MRI data ( Figure 1A ). This sheet was uploaded centrally and accessed when planning the tissue sampling to take a transverse slice towards the apex, mid gland or base as indicated, and then take a 3 mm or 6 mm tissue punch from the region identified as containing a suspicious lesion.
| Optimized method
Following review of the surgical planning sheet, MRI images were by a ruler in mm ( Figure 1C ). After the first 6 cases were sampled, an additional step was carried out to identify any shrinkage that could affect the accuracy of this method. Here, length of the prostate was measured from base to apex on the coronal T2 MRI image, and compared with the length of the prostate measured by ruler immediately before slicing.
Based upon the amount of shrinkage observed an ad hoc correction was applied before identifying the position to slice. Exclusion criteria were applied to omit patients who had undergone prior therapy, had no distinct lesion by MRI (ie, only diffuse changes) and patients who had lesions smaller than 5 mm visible on MRI.
| Tissue storage
Tissue cores were stored depending on the individual study. At least one core from each patient was embedded in optimized cutting temperature compound (OCT), snap frozen in liquid nitrogen immediately and then stored at −80°C. For subsets of cases, additional benign or tumor tissue was either snap frozen dry in cryovials in liquid nitrogen, fixed immediately in 10% neutral buffered formalin and stored as FFPE blocks, or transported in warm media for ex vivo culture (ex vivo culture was not carried out where prostates had been stored overnight before sampling).
| Assessment of tumor content
All 84 samples assessed for tumor content had been stored frozen in OCT. Samples were sectioned at 5 μm thickness using sterile technique on the cryostat, then stained immediately with haematox- Transverse slice taken at base, mid or apex of prostate, and biopsy punches taken based on surgical planning sheet sketches.
Optimized method
Surgical planning sheet reviewed (biopsy and MRI notes and sketches from radiologists, pathologists and surgeons)
Prior therapy MRI review: Identification of index lesion based on surgical planning sheet, measurement of prostate length (base − apex, mm) and distance from base to desired transverse slice (mm).
No observable lesion, or only diffuse changes by MRI Prostate measured, correction factor applied if shrinkage had occurred and transverse slice taken at measured position from base, then biopsy punches taken based on surgical planning sheet sketches and visibility or palpability of tumor where possible.
Lesion smaller than 5 mm
The first 25 patients recruited under PEOPLE were part of an initial cohort, where a basic tumor targeting approach was used and outlined here. The following 59 specimens were sampled using an optimized approach with more specific MRI targeting, also outlined here.
FIGURE 1 Tumor Targeting Methods. Following review of the surgical planning sheet, the index lesion is identified in MRI images. The position of the optimal transverse slice is identified and a measurement is taken from the base to this position and from the base to apex using a coronal T2 weighted image (A). The position of the tumor is noted, here in an axial T2 weighted image (B). Following radical prostatectomy, the full surgical margins are inked right side blue, left side black according to local protocol, then the prostate is measured from base to apex and a correction factor is applied if the prostate has shrunk in comparison with the MRI image. The position of the desired 5 mm transverse slice is identified (C). Following slicing, the area of expected tumor is confirmed if possible visually and/or palpably, with some tumors appearing paler and denser than benign tissue. 6 mm biopsy punches are used to remove samples from indicated tumor and benign areas (D). One tumor sample is submitted to Genomics England for DNA extraction, quality control, whole genome sequencing and data analysis as part of the 100 000 Genomes Project (E). Matched tumor and benign samples are submitted for use in ex vivo gelatin sponge culture, or other ethically approved research projects in a subset of cases (F). [Color figure can be viewed at wileyonlinelibrary.com] assessed using the Nanodrop Fluorometer (ThermoFisher) according to manufacturer's instructions.
| Ex vivo culture
Ex vivo culture was carried out using the gelatin sponge method. 
| RESULTS
Eighty-four prostates were sliced and sampled for various research projects under the PEOPLE pathway, with tumors targeted using the initial method for 25 prostates and optimized method for 59 prostates (Figure 1 ). Patient characteristics are reported in Table 1 . All surgery was carried out in UCLH and MRIs were carried out in 13 different hospitals across Greater London and Essex (Table 2) .
After the first 25 cases a detailed case review was carried out and seven cases were identified where the tumor was missed. All could potentially have been accurately targeted had the transverse slice been taken more towards the base or apex of the prostate (Supplementary Data File S1). This resulted in a change to the optimized method where measurements from the MRI image were used to target the transverse slice and tumor.
In order to account for shrinkage that can occur following surgery, 46 prostates were measured using a ruler from base to apex, and compared with MRI measurements of the same distance. The majority of prostates did shrink, with a mean shrinkage of 5.71 ± 10.57% and a trend towards larger prostates shrinking more and smaller prostates shrinking less (P = 0.0002) (Figure 2A ). Some prostates increased in size, possibly due to growth between the time the MRI image was taken and surgery.
All tumor samples were assessed for tumor content by a consultant uro-pathologist, using frozen H&E sections. Forty percent of samples taken using the initial method and 60% of samples taken using the optimized method had tumor content of at least 40%, and therefore could be submitted without macrodissection for sequencing under the 100,000 Genomes Project ( Figure 2B ). Samples that had between 5 and 30% tumor content were considered 'partial hits' and could potentially be used for sequencing following macrodissection. The sum of hits and partial hits for the initial method was 64% and for the optimized method was 70% ( Figure 2C ).
As well as the risk of missing the tumor when taking the transverse slice, there was also a risk of missing the tumor within the slice when taking punch biopsies. It appeared that accuracy in hitting tumor within the slice improved slightly over time, although this trend was not statistically significant (P = 0.344), based on measurements taken from the sampled area to the nearest tumor within that slice ( Figure 2D ).
The crucial aspect of the PEOPLE method is tumor targeting, and in order to maximize the efficacy of this we used both MRI and biopsy data to assess tumor location within the prostate for sampling. Where biopsy and MRI data did not agree, both indicated areas were targeted if possible, and if not, MRI data was used alone. Figure S1F) .
Thirty-nine samples were submitted for sequencing under the 100 000 Genomes Project. DNA was eluted in a final volume of 70 μL, and was analyzed using spectrophotometry. All had 260:280 ratios of 1.8-2.0, with an average concentration of 41.7 ± 18.92 ng/μL.
Cellularity of each sample was noted by a pathologist as very low (<700 total cells), low (4000 cells), medium (4000-10 000 total cells), high (>10 000 total cells), very high (>50 000 total cells), and there was no significant difference in DNA concentration between each cellularity grouping ( Figure 2F ).
FIGURE 2
Key data from case review. Prostate length was measured in mm in MRI images and using a ruler post-surgery and an ad hoc correction for shrinkage applied each time prior to slicing (A). tumor content was assessed by a uropathologist based on H&E staining of frozen sections of tumor targeted samples. Mean tumor content was 29.6% for the initial targeting method and 44.8% for the optimized targeting method. All samples above the threshold of 40% tumor content were deemed eligible for next generation sequencing as per 100 000 Genome Project Guidelines. A two tailed Mann-Whitney was performed and the difference between the two cohorts was deemed non-significant (B). Samples where 5-40% tumor was identified were noted as "partial hits" and could be macrodissected in order to be submitted for next generation sequencing. C, Distance from punch taken to nearest tumor on the same slice was measured and plotted sequentially in the order of patients sampled, with linear regression not identifying a significantly non-zero slope (D). The location of most significant tumor was recorded based on MRI, biopsy and radical prostatectomy data. It was recorded whether MRI, biopsy, both or neither best indicated the location of most significant disease post radical prostatectomy (E). DNA was isolated from 39 cases for next generation sequencing under the 100 000 Genomes Project. Almost all cases yielded concentrations over 20 ng/μL and those that did not were repeated with more sections and submitted for sequencing. Data is noted for the first DNA isolation of each case, with non-significant q values from a one way ANOVA and Tukey test (F)
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Three samples were cultured ex vivo using the gelatin sponge method. 12 Control samples were stored as FFPE blocks at the time of sampling and after 72 h culture at 37°C, and 4 μm sections were stained with H&E, the proliferation marker Ki67 and apoptosis marker cleaved caspase 3. Minimal-no differences in morphology, proliferation or apoptosis were noted between cultured and uncultured samples in cases one and two, while some loss of tissue integrity was noted for patient three, which could be optimized in future using different media or shorter culture.
( Figure 3 ).
FIGURE 3
Ex vivo culture Tissue from three cases was cultured ex vivo for 72 h using the gelatin sponge method. Samples were stored as FFPE blocks after 72 h (untreated tissue), with matched uncultured samples also stored FFPE (uncultured tissue). Sections were then stained with H&E (morphology), Ki67 (proliferation) and cleaved caspase-3 (apoptosis) to assess whether tissue from PEOPLE is of sufficient quality for culture. suggested the use of imaging and biopsy data to better target lesions for sampling. 13 Here, we address this by using MRI to target specific areas of tissue that can then be used immediately for research, vastly increasing the range of experimental techniques that can be exploited, while still integrating well within the clinical pathway.
Previous prostate tissue collection methods have sampled areas of the gland randomly, or by palpating or viewing the tumor as slightly more dense or pale. These methods are sufficient for certain downstream techniques, but are unlikely to be reliable for routine collection of high tumor content samples based upon our data that demonstrates that the average tumor only occupies 11% of the overall prostate volume, and is often not discernible by eye or touch from the surrounding benign tissue ( Figure 1D ). MRI has been heralded as a major step forward for prostate cancer diagnosis, with findings from multiple clinical trials advocating its routine use. [8] [9] [10] [11] With this gain in popularity comes an opportunity for researchers to exploit MRI data to improve fresh tissue collection, here allowing us to successfully target tumor in 70% of samples ( Figure 2C ).
We have incorporated MRI into the sampling method in order to improve tumor targeting and whilst UCLH is a world leader in MRI, most patients in our cohort had imaging at one of twelve other hospitals across the Greater London / Essex area before coming for surgery at UCLH. The varying quality of the MRI data did not impact on our ability to target tumors and we predict that this method can be successful wherever MRI is carried out prior to surgery ( Table 2 ).
The major disadvantage of previous methods was the lack of confidence in the pathology of the sampled tissue that limited its utility and often required extensive sampling and/or pathologist time to identify samples with high tumor content. 2, 3 The key benefit of incorporating MRI guided tumor targeting into the sample collection pathway is the increased freedom this provides to carry out a much wider range of downstream experiments. As with previous methodologies, samples can be stored in RNAlater for expression analysis, fixed and stored as FFPE for immunohistochemistry, or frozen for genomics studies, all with greater confidence in the content of each sample prior to histological assessment. 4, 5 Here, tumor samples were frozen and DNA of consistently high purity and quantity for sequencing was isolated for the 100,000 Genomes Project ( Figure 2F show that untreated tissue post culture had minimal degradation in morphology, proliferation and apoptosis as uncultured tissue ( Figure 3 ). As prostate cancer research progresses, we predict more methods will emerge which require high quality fresh tumor tissue. In order to do these experiments using previously described tissue collection methods, researchers would need to over-collect samples and use a substantial excess to ensure presence of tumor. This is unfeasible in terms of both cost, time and an unethical use of human tissue that could be better utilized in other studies.
Although this method contains additional steps compared with previously published methods, including our own, we succeeded in reducing the time burden on clinical staff using a protocol that dovetailed with the standard clinical pathway and could be performed by trained postdoctoral researchers and technicians. 7 This included measurement of MRI data, meaning the only radiology department input required was for training at the beginning of the study. This reduced the burden on the overall clinical system and allowed for flexible sample collection for research projects when required by the researchers. Additionally, surgical margins and diagnostic tissue are preserved as before. 
| CONCLUSIONS
We report our initial data from the PEOPLE pathway, an improvement to our previously published prostate slicing method, where we utilize MRI data to target and collect high quality tumor and benign prostate tissue that can be used for a wide variety of research applications such as next generation sequencing or ex vivo culture, with minimal impact on the clinical pathway.
